Literature DB >> 19737892

Kinetics of the immune response profile in guinea pigs after vaccination with Mycobacterium bovis BCG and infection with Mycobacterium tuberculosis.

Ajay Grover1, Jennifer Taylor, JoLynn Troudt, Andrew Keyser, Kimberly Arnett, Linda Izzo, Drew Rholl, Angelo Izzo.   

Abstract

The guinea pig model of tuberculosis is used extensively in assessing novel vaccines, since Mycobacterium bovis BCG vaccination effectively prolongs survival after low-dose aerosol infection with virulent M. tuberculosis. To better understand how BCG extends time to death after pulmonary infection with M. tuberculosis, we examined cytokine responses postvaccination and recruitment of activated T cells and cytokine response postinfection. At 10 weeks postvaccination, splenic gamma interferon (IFN-gamma) mRNA was significantly elevated compared to the levels at 5 weeks in ex vivo stimulation assays. At 15, 40, 60, and 120 days postinfection, T-cell activation (CD4+ CD62Llow and CD8+ CD62Llow) and mRNA expression of IFN-gamma, tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), IL-10, IL-12, and eomesodermin were assessed. Our data show that at day 40, BCG-vaccinated guinea pigs had significantly increased levels of IFN-gamma mRNA expression but decreased TNF-alpha mRNA expression in their lungs compared to the levels in nonvaccinated animals. At day 120, a time when nonvaccinated guinea pigs succumbed to infection, low levels of IFN-gamma mRNA were observed even though there were increasing levels of IL-1, IL-12, and IL-10, and the numbers of activated T cells did not differ from those in BCG-vaccinated animals. BCG vaccination conferred the advantage of recruiting greater numbers of CD4+ CD62Llow T cells at day 40, although the numbers of CD8+ CD62Llow T cells were not elevated compared to the numbers in nonvaccinated animals. Our data suggest that day 40 postinfection may be a pivotal time point in determining vaccine efficacy and prolonged survival and that BCG promotes the capacity of T cells in the lungs to respond to infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19737892      PMCID: PMC2772515          DOI: 10.1128/IAI.00704-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

Review 1.  T-cell function and migration. Two sides of the same coin.

Authors:  U H von Andrian; C R Mackay
Journal:  N Engl J Med       Date:  2000-10-05       Impact factor: 91.245

2.  Antibody to VLA-4, but not to L-selectin, protects neuronal M2 muscarinic receptors in antigen-challenged guinea pig airways.

Authors:  A D Fryer; R W Costello; B L Yost; R R Lobb; T F Tedder; D A Steeber; B S Bochner
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

3.  Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens.

Authors:  T F Tedder; A C Penta; H B Levine; A S Freedman
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

4.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

Authors:  J L Flynn; M M Goldstein; J Chan; K J Triebold; K Pfeffer; C J Lowenstein; R Schreiber; T W Mak; B R Bloom
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

5.  Mycobacterium bovis BCG vaccination augments interleukin-8 mRNA expression and protein production in guinea pig alveolar macrophages infected with Mycobacterium tuberculosis.

Authors:  Mark J Lyons; Teizo Yoshimura; David N McMurray
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 6.  Mycobacterial infection in guinea pigs.

Authors:  V Balasubramanian; E H Wiegeshaus; D W Smith
Journal:  Immunobiology       Date:  1994-10       Impact factor: 3.144

7.  Differential expression of gamma interferon mRNA induced by attenuated and virulent Mycobacterium tuberculosis in guinea pig cells after Mycobacterium bovis BCG vaccination.

Authors:  Amminikutty Jeevan; Teizo Yoshimura; Kyeong Eun Lee; David N McMurray
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

Review 8.  What animal models can teach us about the pathogenesis of tuberculosis in humans.

Authors:  D W Smith; E H Wiegeshaus
Journal:  Rev Infect Dis       Date:  1989 Mar-Apr

9.  Disseminated tuberculosis in interferon gamma gene-disrupted mice.

Authors:  A M Cooper; D K Dalton; T A Stewart; J P Griffin; D G Russell; I M Orme
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

10.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection.

Authors:  J L Flynn; J Chan; K J Triebold; D K Dalton; T A Stewart; B R Bloom
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  20 in total

1.  Bacillus Calmette-Guérin vaccination using a microneedle patch.

Authors:  Yasuhiro Hiraishi; Subhadra Nandakumar; Seong-O Choi; Jeong Woo Lee; Yeu-Chun Kim; James E Posey; Suraj B Sable; Mark R Prausnitz
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

2.  BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity.

Authors:  Andrew Keyser; Jolynn M Troudt; Jennifer L Taylor; Angelo A Izzo
Journal:  Vaccine       Date:  2011-10-18       Impact factor: 3.641

3.  Mycobacterium tuberculosis sigE mutant ST28 used as a vaccine induces protective immunity in the guinea pig model.

Authors:  JoLynn Troudt; Elizabeth Creissen; Linda Izzo; Helle Bielefeldt-Ohmann; Stefano Casonato; Riccardo Manganelli; Angelo A Izzo
Journal:  Tuberculosis (Edinb)       Date:  2017-07-24       Impact factor: 3.131

4.  Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Shaobin Shang; Crystal A Shanley; Megan L Caraway; Eileen A Orme; Marcela Henao-Tamayo; Laurel Hascall-Dove; David Ackart; Ian M Orme; Diane J Ordway; Randall J Basaraba
Journal:  Vaccine       Date:  2012-01-11       Impact factor: 3.641

5.  HspX vaccination and role in virulence in the guinea pig model of tuberculosis.

Authors:  Agatha E Wieczorek; Jolynn L Troudt; Phillip Knabenbauer; Jennifer Taylor; Rebecca L Pavlicek; Russell Karls; Anne Hess; Rebecca M Davidson; Michael Strong; Helle Bielefeldt-Ohmann; Angelo A Izzo; Karen M Dobos
Journal:  Pathog Dis       Date:  2014-02-24       Impact factor: 3.166

6.  Assessment of vaccine testing at three laboratories using the guinea pig model of tuberculosis.

Authors:  Ajay Grover; Jolynn Troudt; Kimberly Arnett; Linda Izzo; Megan Lucas; Katie Strain; Christine McFarland; Yper Hall; David McMurray; Ann Williams; Karen Dobos; Angelo Izzo
Journal:  Tuberculosis (Edinb)       Date:  2011-10-01       Impact factor: 3.131

Review 7.  Animal models of tuberculosis: Guinea pigs.

Authors:  Simon Clark; Yper Hall; Ann Williams
Journal:  Cold Spring Harb Perspect Med       Date:  2014-12-18       Impact factor: 6.915

8.  Three protein cocktails mediate delayed-type hypersensitivity responses indistinguishable from that elicited by purified protein derivative in the guinea pig model of Mycobacterium tuberculosis infection.

Authors:  Hongliang Yang; JoLynn Troudt; Ajay Grover; Kimberly Arnett; Megan Lucas; Yun Sang Cho; Helle Bielefeldt-Ohmann; Jennifer Taylor; Angelo Izzo; Karen M Dobos
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

9.  Portrait of a pathogen: the Mycobacterium tuberculosis proteome in vivo.

Authors:  Nicole A Kruh; Jolynn Troudt; Angelo Izzo; Jessica Prenni; Karen M Dobos
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

10.  Pulmonary mucosal immunity mediated through CpG provides adequate protection against pulmonary Mycobacterium tuberculosis infection in the mouse model. A role for type I interferon.

Authors:  Amber Troy; Sandra C Esparza-Gonzalez; Alicia Bartek; Elizabeth Creissen; Linda Izzo; Angelo A Izzo
Journal:  Tuberculosis (Edinb)       Date:  2020-06-06       Impact factor: 3.131

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.